LEADER 04471nam 22011293u 450 001 9910785176703321 005 20230721013409.0 010 $a1-60876-345-5 035 $a(CKB)2670000000041771 035 $a(EBL)3018501 035 $a(SSID)ssj0000428798 035 $a(PQKBManifestationID)11323185 035 $a(PQKBTitleCode)TC0000428798 035 $a(PQKBWorkID)10425014 035 $a(PQKB)10059308 035 $a(MiAaPQ)EBC3018501 035 $a(EXLCZ)992670000000041771 100 $a20151005d2008|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aStatins$b[electronic resource] $eIndications and Uses, Safety and Modes of Action 210 $aNew York $cNova Science Publishers, Inc.$d2008 215 $a1 online resource (219 p.) 300 $aDescription based upon print version of record. 311 $a1-60692-103-7 327 $aStatin therapy for coronary artery disease beyond lipid lowering effect / Teruo Inoue, Koichi Node -- Side effects of statins in monotherapy / Helmut Sinzinger, Bernhard A. Peskar -- Preliminary findings about the trends of the renal hemodynamics and the proxies of cardiovascular risk during a short course of atorvastatin therapy in essential hypertensives / Luigi Vernaglione -- Beneficial effects of addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions / Hetal D. Shah ... [et al.] -- Non-lipid lowering effects of statins / A. Schmidt -- Statins in the therapy of acute coronary syndrome / Petr Ostadal -- Beneficial effects of addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions / Hetal D. Shah ... [et al.] -- Bad HDL-C responders to statins / Dirk Devroey -- Beneficial effects of statins in systemic lupus erythematosus : molecular mechanism involved / Antonio G. Tristano. 606 $aAnticholesteremic agents 606 $aStatins (Cardiovascular agents) 606 $aStatins (Cardiovascular agents) 606 $aLipoproteins, LDL 606 $aAnticholesteremic Agents 606 $aVascular Diseases 606 $aCholesterol 606 $aEnzyme Inhibitors 606 $aHeart Diseases 606 $aCholesterol, LDL 606 $aHydroxymethylglutaryl-CoA Reductase Inhibitors 606 $aMyocardial Ischemia 606 $aSterols 606 $aHypolipidemic Agents 606 $aLipoproteins 606 $aCardiovascular Diseases 606 $aMolecular Mechanisms of Pharmacological Action 606 $aAntimetabolites 606 $aProteins 606 $aLipid Regulating Agents 606 $aLipids 606 $aDiseases 606 $aPharmacologic Actions 606 $aMembrane Lipids 606 $aTherapeutic Uses 606 $aChemical Actions and Uses 606 $aAmino Acids, Peptides, and Proteins 606 $aHealth & Biological Sciences$2HILCC 606 $aPharmacy, Therapeutics, & Pharmacology$2HILCC 615 4$aAnticholesteremic agents. 615 4$aStatins (Cardiovascular agents). 615 0$aStatins (Cardiovascular agents) 615 2$aLipoproteins, LDL 615 2$aAnticholesteremic Agents 615 2$aVascular Diseases 615 2$aCholesterol 615 2$aEnzyme Inhibitors 615 2$aHeart Diseases 615 2$aCholesterol, LDL 615 2$aHydroxymethylglutaryl-CoA Reductase Inhibitors 615 2$aMyocardial Ischemia 615 2$aSterols 615 2$aHypolipidemic Agents 615 2$aLipoproteins 615 2$aCardiovascular Diseases 615 2$aMolecular Mechanisms of Pharmacological Action 615 2$aAntimetabolites 615 2$aProteins 615 2$aLipid Regulating Agents 615 2$aLipids 615 2$aDiseases 615 2$aPharmacologic Actions 615 2$aMembrane Lipids 615 2$aTherapeutic Uses 615 2$aChemical Actions and Uses 615 2$aAmino Acids, Peptides, and Proteins 615 7$aHealth & Biological Sciences 615 7$aPharmacy, Therapeutics, & Pharmacology 676 $a615/.718 700 $aHolmqvist$b Gunnar N$01482369 702 $aHolmqvist$b Gunnar N 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910785176703321 996 $aStatins$93699943 997 $aUNINA